Kurt M Eichler Form 4 Spring Bank Pharmaceuticals / Kurt M Eichler ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Eichler Kurt M

(Last) (First) (Middle)

C/O SPRING BANK PHARMACEUTICALS, INC.

86 SOUTH STREET

(Street)

HOPKINTON MA 01748

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Spring Bank Pharmaceuticals, Inc. [ SBPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2016

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/11/2016		P(1)		41,666	A	$12	423,990	D
Common Stock	05/11/2016		X		9,375	A	$8	19,375	I	See Footnote(2)
Common Stock	05/11/2016		X		9,375	A	$8	19,375	I	See Footnote(3)
Common Stock	05/11/2016		X		9,375	A	$8	19,375	I	See Footnote(4)
Common Stock	05/11/2016		X		9,375	A	$8	19,375	I	See Footnote(5)
Common Stock	05/11/2016		X		10,416	A	$9	29,791	I	See Footnote(2)
Common Stock	05/11/2016		X		10,416	A	$9	29,791	I	See Footnote(3)
Common Stock	05/11/2016		X		10,416	A	$9	29,791	I	See Footnote(4)
Common Stock	05/11/2016		X		10,416	A	$9	29,791	I	See Footnote(5)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant (right to buy)	$8	05/11/2016		X			9.375	(6)	10/26/2017	Common Stock	9,375	$0.00	0	I	See Footnote(7)
Warrant (right to buy)	$8	05/11/2016		X			9.375	(6)	10/26/2017	Common Stock	9,375	$0.00	0	I	See Footnote(8)
Warrant (right to buy)	$8	05/11/2016		X			9.375	(6)	10/26/2017	Common Stock	9,375	$0.00	0	I	See Footnote(9)
Warrant (right to buy)	$8	05/11/2016		X			9.375	(6)	10/26/2017	Common Stock	9,375	$0.00	0	I	See Footnote(10)
Warrant (right to buy)	$9	05/11/2016		X			10,416	(6)	12/13/2018	Common Stock	10,416	$0.00	0	I	See Footnote(7)
Warrant (right to buy)	$9	05/11/2016		X			10,416	(6)	12/13/2018	Common Stock	10,416	$0.00	0	I	See Footnote(8)
Warrant (right to buy)	$9	05/11/2016		X			10,416	(6)	12/13/2018	Common Stock	10,416	$0.00	0	I	See Footnote(9)
Warrant (right to buy)	$9	05/11/2016		X			10,416	(6)	12/13/2018	Common Stock	10,416	$0.00	0	I	See Footnote(10)

Explanation of Responses:

1. Reports the purchase of shares in the underwritten public offering of common stock of Spring Bank Pharmaceuticals, Inc.

2. These shares are directly held by Emerson Eichler, the Reporting Person's immediate family member.

3. These shares are directly held by Katherine Eichler, the Reporting Person's immediate family member.

4. These shares are directly held by Lindsay Eichler, the Reporting Person's immediate family member.

5. These shares are directly held by Pauline Eichler, the Reporting Person's immediate family member.

6. The warrants were immediately exercisable.

7. These warrants were directly held by Emerson Eichler, the Reporting Person's immediate family member.

8. These warrants were directly held by Katherine Eichler, the Reporting Person's immediate family member.

9. These warrants were directly held by Lindsay Eichler, the Reporting Person's immediate family member.

10. These warrants were directly held by Pauline Eichler, the Reporting Person's immediate family member.

Remarks:

	/s/ Jonathan Freve, attorney-in-fact	05/11/2016
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.